Patent 6989369 was granted and assigned to Dyax on January, 2006 by the United States Patent and Trademark Office.
The invention relates to a Kunitz domain peptide, designated DPI-14 herein, for inhibiting human neutrophil elastase. The invention also relates to a method of using a DPI-14 for treating cystic fibrosis or cystic fibrosis-related disease or disorder.